Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors01:30

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

2.2K
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
2.2K
Antihypertensive Drugs: Direct Renin Inhibitors01:25

Antihypertensive Drugs: Direct Renin Inhibitors

1.2K
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
1.2K
Antihypertensive Drugs: Angiotensin II Receptor Blockers01:30

Antihypertensive Drugs: Angiotensin II Receptor Blockers

2.3K
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
2.3K
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

849
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
849
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

1.2K
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
1.2K
Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

1.3K
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....
1.3K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Virtual reality training for cognitive impairment in adults treated with haemodialysis (VIRTUAL): protocol for a multicentre, randomised, open-label feasibility trial.

BMJ open·2026
Same author

The Neglected Older Adults in Hereditary Angioedema: Insights From the ITACA Registry.

Clinical and translational allergy·2026
Same author

Vessel-sealing devices may be safely used for hepatic surgery in dogs with a low rate of severe complications.

American journal of veterinary research·2026
Same author

Outcome and complications of lateral caudal axial pattern flap in 14 cats.

Veterinary surgery : VS·2025
Same author

Thoracoscopic resection of cranial mediastinal masses: Retrospective study in 17 cats.

Veterinary surgery : VS·2025
Same author

Assessment of potential drug-drug interactions in patients with hereditary angioedema from the ITACA cohort: simulations from a real-life dataset considering danazol versus berotralstat.

Frontiers in pharmacology·2025

Related Experiment Video

Updated: Jan 2, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

38.9K

ACE inhibitor-mediated angioedema.

Vincenzo Montinaro1, Marco Cicardi2

  • 1Division of Nephrology, Azienda Ospedaliero-Universitaria Policlinico Consorziale, Bari, Italy.

International Immunopharmacology
|December 14, 2019
PubMed
Summary

Angioedema during ACE inhibitor therapy (ACEi-AE) is rare but serious. Bradykinin accumulation is key, with ethnic and genetic factors influencing risk and treatment response.

More Related Videos

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

16.9K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.5K

Related Experiment Videos

Last Updated: Jan 2, 2026

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice
07:21

Subcutaneous Angiotensin II Infusion using Osmotic Pumps Induces Aortic Aneurysms in Mice

Published on: September 28, 2015

38.9K
Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery
09:41

Vascular Balloon Injury and Intraluminal Administration in Rat Carotid Artery

Published on: December 23, 2014

16.9K
A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis
08:21

A Modified Two Kidney One Clip Mouse Model of Renin Regulation in Renal Artery Stenosis

Published on: October 26, 2020

5.5K

Area of Science:

  • Cardiology and Pharmacology
  • Immunology and Genetics

Background:

  • Angioedema (AE) is a rare complication of ACE inhibitor (ACEi) therapy (ACEi-AE), affecting 0.1-0.7% of patients.
  • Other medications can increase ACEi-AE risk. Ethnic and genetic predispositions are noted, with higher prevalence in African-Americans and Hispanics.
  • While some recurrence may occur with angiotensin-receptor blockers (ARBs), large studies show ARBs do not increase AE likelihood compared to other antihypertensives.

Purpose of the Study:

  • To review the epidemiology, clinical manifestations, pathogenesis, and treatment of ACE inhibitor-induced angioedema (ACEi-AE).
  • To explore the role of bradykinin metabolism, genetic factors, and ethnic predispositions in ACEi-AE.
  • To discuss current treatment strategies and their efficacy, including emerging therapies.

Main Methods:

  • Literature review of epidemiological studies, clinical case reports, and genetic research on ACEi-AE.
  • Analysis of the role of the renin-angiotensin aldosterone system (RAAS) and bradykinin in AE pathogenesis.
  • Evaluation of treatment outcomes for various interventions, including bradykinin receptor antagonists.

Main Results:

  • ACEi-AE involves bradykinin accumulation due to reduced ACE metabolism. Ethnic and genetic factors influence prevalence and potentially treatment response.
  • Clinical features include facial, lingual, and airway edema, with potential intestinal involvement. Attacks are prolonged and often require hospitalization.
  • Standard treatments like corticosteroids and antihistamines are ineffective. Fresh frozen plasma, C1 inhibitor concentrate, and icatibant show variable efficacy, possibly with ethnic differences.

Conclusions:

  • ACEi-AE pathogenesis is linked to bradykinin dysregulation, influenced by genetics and ethnicity.
  • Effective treatment remains challenging, with ongoing research into specific bradykinin pathway modulators.
  • Understanding ethnic predispositions is crucial for optimizing therapeutic strategies for angioedema.